Abstract: A climate-controlled freight container (10) comprises a casing (12), enclosing a cargo compartment (20) and a control compartment (26). The container further comprises a climate system (30) that has at least two climate modules (40) and an air distribution arrangement (21), configured to distribute air from the climate system into the cargo compartment and. A central climate-control unit (52) is configured for collection of measurements associated with climate conditions of the cargo compartment and for controlling the climate system. Each of the climate modules is configured for adapting climate properties of air flowing through the climate modules from a return air plenum (36) to a supply air plenum (34). Each of the at least two climate modules comprises a local climate-control unit (46), configured for controlling an operation of the climate module. The central climate-control unit is configured for providing operational instructions to the local climate-control units.

Abstract: A temperature-controlled transport container (10) has a cargo space (1) for accommodating temperature-sensitive goods and a refrigeration system. The refrigeration system comprises a closed air circuit (2), separate from the cargo space and located outside of and contiguous with at least one wall (9) of the cargo space. The refrigeration system further comprises at least one refrigeration unit (5) configured to cool air in the closed air circuit. The refrigeration system also comprises a pressurizing unit (8) for establishing a pressure difference between the closed air circuit and the ambient environment (20) outside of, but in a vicinity of, the temperature-controlled transport container.

Abstract: A freight container (10), comprising: a cargo compartment being defined by a floor (16), a ceiling (14) and walls (18a-d) wherein the ceiling comprises an inner portion (40) and an outer portion (24) defining a first space (26). The freight container further comprises a climate arrangement (50), configured for providing a climate-conditioned air-flow into said cargo compartment of said freight container. At least one of said walls comprises an inner wall portion (17a, 42) and an outer wall portion (17b, 32) defining a second space (19a, 19b), wherein said first space is fluidically connected to said second space, and said inner wall portion comprises at least one aperture (110) between said second space and said cargo compartment. The climate arrangement is configured to provide said climate-conditioned air-flow into said cargo compartment of said freight container via said first space, said second space and said at least one aperture.

Abstract: The present invention relates to a MEK inhibitor and compositions thereof, for use in the treatment of stroke, in particular treatment of subarachnoid haemorrhage (SAH)

Abstract: The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample, wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein said at least one light source and said at least one detector are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample (200), wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein at least one light source (204) and at least one detector (205) are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample (200), wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein at least one light source (204) and at least one detector (205) are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C (PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.

Abstract: The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C(PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.

Abstract: A method of preventing or alleviating renal disorders by administering to a human or an animal in need thereof a pharmaceutical composition comprising an effective amount amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.

Abstract: The present invention relates to the use of inositoltrisphosphate (IP.sub.3) for the preparing of a medicament effective as a neuropeptide Y- (NPY-) antagonist and to a pharmaceutical composition comprising at least one specific isomer of IP.sub.3 and a pharmaceutically active compound effective in the cardiovascular, renal and/or cerebral area.

Abstract: A method of preventing or alleviating certain conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.